Trial · NCT02705755
Participant flow76
How many started, completed or left each group, period by period.
1 to 20 of 76
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A (6 Days) | STARTED | Part A: Dose Escalation (Within Group) | 34 | |
| Part A (6 Days) | STARTED | Part B: Randomized - Placebo | 0 | |
| Part A (6 Days) | STARTED | Part B: Randomized- TD-9855 | 0 | |
| Part A (6 Days) | STARTED | Part C: Dose Extension | 0 | |
| Part A (6 Days) | Participants Who Received Placebo | Part A: Dose Escalation (Within Group) | 34 | |
| Part A (6 Days) | Participants Who Received Placebo | Part B: Randomized - Placebo | 0 | |
| Part A (6 Days) | Participants Who Received Placebo | Part B: Randomized- TD-9855 | 0 | |
| Part A (6 Days) | Participants Who Received Placebo | Part C: Dose Extension | 0 | |
| Part A (6 Days) | Participants Who Received 1 mg Study Drug | Part A: Dose Escalation (Within Group) | 17 | |
| Part A (6 Days) | Participants Who Received 1 mg Study Drug | Part B: Randomized - Placebo | 0 | |
| Part A (6 Days) | Participants Who Received 1 mg Study Drug | Part B: Randomized- TD-9855 | 0 | |
| Part A (6 Days) | Participants Who Received 1 mg Study Drug | Part C: Dose Extension | 0 | |
| Part A (6 Days) | Participants Who Received 2.5 mg Study Drug | Part A: Dose Escalation (Within Group) | 31 | |
| Part A (6 Days) | Participants Who Received 2.5 mg Study Drug | Part B: Randomized - Placebo | 0 | |
| Part A (6 Days) | Participants Who Received 2.5 mg Study Drug | Part B: Randomized- TD-9855 | 0 | |
| Part A (6 Days) | Participants Who Received 2.5 mg Study Drug | Part C: Dose Extension | 0 | |
| Part A (6 Days) | Participants Who Received 5 mg Study Drug | Part A: Dose Escalation (Within Group) | 29 | |
| Part A (6 Days) | Participants Who Received 5 mg Study Drug | Part B: Randomized - Placebo | 0 | |
| Part A (6 Days) | Participants Who Received 5 mg Study Drug | Part B: Randomized- TD-9855 | 0 | |
| Part A (6 Days) | Participants Who Received 5 mg Study Drug | Part C: Dose Extension | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02705755/flow